Preparation and biological evaluation of radiolabeled-folate embedded superparamagnetic nanoparticles in wild-type rats
- 210 Downloads
In this study, superparamagnetic iron oxide nanoparticles (SPION) embedded by folic acid (SPION-folate) were prepared by a modified co-precipitation method. The structure, size, morphology, magnetic property and relaxivity of the SPION-folate were characterized systematically by means of XRD, VSM, HRSEM and TEM and the interaction between folate and iron oxide (Fe3O4) was characterized by FT-IR. The particle size was shown to be ≈5–10 nm. To ensure biocompatibility, the interaction of these SPION with mouse connective tissue cells (adhesive) was investigated using an MTT assay. Consequently, gallium-67 labeled nanoparticles ([67Ga]-SPION-folate) were prepared using 67Ga with a high labeling efficiency (over 96%, RTLC method) and they also showed an excellent stability at room temperature for at least 2 days and were evaluated for their biodistribution in normal rats up to 24 h compared with free Ga3+ cation and [67Ga]-SPION biodistribution. The biodistribution of the tracer among 3 other folate tracers were compared, showing lower liver uptake and higher blood circulation after 24 h leading to better bioavailability. The bone:muscle, kidney:muscle, lung:muscle, stomach:muscle ratios were 9.3, 9.32, 7.6 and 5.83 respectively. The developed folate-containing nano-system can be an interesting folate receptor tracer, capable of better cell membrane permeability while possessing paramagnetic properties for thermotherapy.
KeywordsSPION 67Ga Folate Biodistribution Quality control
Authors wish to thank Mr S. Daneshvari for conducting animal studies and radioisotope production team at Nuclear Medicine Research Group and Dr. M. A. Rowshanzamir for editorial corrections.
- 2.Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24(5 Suppl 18):S18–30–9 (PMID 9420019)Google Scholar
- 3.Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51(19):5329–5338Google Scholar
- 5.Wu M, Gunning W, Ratnam M (1999) Expression of folate receptor type a in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomark Prev 8:775–783Google Scholar
- 9.Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9(12):1277–1286Google Scholar
- 10.Rossin R, Pan D, Qi MS, Turner JL, Sun X, Wooley KL, Welch MJ (2005) 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 46:1210–1218Google Scholar
- 13.Pieters R, Huismans DR, Leyva A, Veerman AJP (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 59:217–220Google Scholar
- 14.Fowlkes WY, Creveling CM (1995) Engineering methods for robust product design: using Taguchi methods in technology and product development. Prentice Hall, New YorkGoogle Scholar
- 18.Cornell RM, Schertmann U (1991) Iron oxides in the laboratory: preparation and characterization. VCH, WeinheimGoogle Scholar
- 23.Reddy JA, Xu L-C, Parker N, Vetzel M, Leamon CP (2004) Preclinical evaluation of 99mTc-EC20 for imaging, folate receptor—positive tumors. J Nucl Med 45:857–866Google Scholar
- 25.Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Mark A (1998) Green indium-111In-DTPA-folate as a potential folate receptor-targeted radiopharmaceutical. J Nucl Med 39:1579–1585Google Scholar
- 26.Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Mark A (1996) Green tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 37:1003–1008Google Scholar